Skip to main content
. 2023 Mar 28;15(7):2010. doi: 10.3390/cancers15072010

Figure 4.

Figure 4

Aptamer-based strategies to restore an antitumoral immune TME. In TNBC, aptamers have been used for: (a) potentiating the cytotoxic activity of CD8+ T cells; (b) blocking immune checkpoint proteins from binding with their partners; and (c) restoring antitumoral TME through the recruitment of aptamer-engineered immune cells (macrophages and NK cells) to the tumor (see text for details). Created with BioRender.com (accessed on 2 March 2023).